Axon Enterprise SEC Filings

Axon Enterprise, Inc. officer Jeffrey C. Kunins reported an equity award event involving 20,618 shares of common stock. These shares relate to performance-based restricted stock units (XSUs) granted on December 22, 2023 under the Axon Enterprise, Inc. 2024 eXponential Stock Plan, for which the third tranche performance conditions were certified as met on November 13, 2025.

The tranche is scheduled to vest on June 1, 2026, contingent on continued employment through that date. After vesting, the delivered shares are subject to a minimum holding period until the earlier of December 31, 2030 or the vesting of a later XSU tranche, excluding shares used to cover taxes. Following the reported transaction, Kunins beneficially owns 94,563 shares directly and 70,593 shares indirectly through an LLC of which he is the sole member.

Axon Enterprise, Inc. (AXON) reported that its Chief Executive Officer and director received 97,015 shares of common stock on 11/13/2025 through performance-based restricted stock units tied to tranche 3 of the 2024 CEO Performance Award. The Compensation Committee certified that the performance conditions were achieved on that date, triggering the award. These units are scheduled to vest on December 31, 2029, subject to the CEO’s continued employment. After this transaction, the CEO beneficially owns 3,120,997 shares of Axon common stock directly. Vested shares from each tranche are subject to a minimum holding period until the earlier of December 31, 2030 or the vesting of a subsequent tranche, other than shares withheld for taxes.

Axon Enterprise, Inc. (AXON) reported an insider equity award for its Chief Revenue Officer. On 11/13/2025, 15,810 shares of common stock were acquired at a price of $0, increasing the officer’s directly held stake to 60,278 shares. These shares relate to performance-based restricted stock units (XSUs) originally granted on April 1, 2024, for which the performance conditions for the third tranche were certified as achieved on that date.

The certified tranche will vest on October 1, 2026, subject to continued employment through that date. After vesting, the delivered shares are subject to a minimum holding period until the earlier of December 31, 2030 or the vesting of a subsequent XSU tranche, other than any shares withheld or sold to cover taxes.

Axon Enterprise, Inc. officer reports equity award vesting and tax withholding transactions. The company’s Chief Accounting Officer acquired 3,906 shares of Axon common stock on 11/13/2025 at a stated price of $0, reflecting performance-based restricted stock units from a 2023 grant under the 2024 eXponential Stock Plan, for which the third tranche performance conditions were certified on that date. On the same day, 2,277 shares were disposed of at $557.29 per share, representing shares withheld to cover the reporting person’s tax liability from vesting. After these transactions, the officer directly owned 16,632 shares of Axon common stock. The vested tranche is scheduled to fully vest on June 1, 2026, subject to continued employment, and the delivered shares will be subject to a minimum holding period until the earlier of December 31, 2030 or the vesting of a subsequent tranche, excluding shares used to cover taxes.

Axon Enterprise, Inc. reported an equity award event for its COO & CFO, Brittany Bagley. On 11/13/2025, she acquired 30,560 shares of Axon common stock at a price of $0, reflecting the certification of performance conditions for the third tranche of performance-based restricted stock units (XSUs) granted on December 22, 2023 under the Axon Enterprise, Inc. 2024 eXponential Stock Plan. These XSUs relate to a tranche whose performance goals were certified as achieved by the Compensation Committee on that date. After this transaction, she beneficially owns 121,652 shares of common stock directly. The tranche is scheduled to vest on June 1, 2026, subject to continued employment, and the shares delivered will be subject to a minimum holding period until the earlier of December 31, 2030 or the vesting of a subsequent XSU tranche, excluding shares used to cover taxes.

Axon Enterprise (AXON) insider transaction: On 11/10/2025, an officer serving as COO & CFO reported a sale of common stock under Form 4. The filing lists a disposition of 2,500 shares at $610 per share (transaction code “S”).

Following the sale, the insider beneficially owned 91,092 shares, held directly. The filing was made by one reporting person.

Axon Enterprise (AXON) disclosed that its Chief Executive Officer and Director sold 10,000 shares of common stock on 11/07/2025 in multiple transactions executed under a Rule 10b5-1 trading plan adopted on May 12, 2025. The trades were reported across price tranches, with individual weighted-average sale prices noted, ranging from $579.4601 to $610.58. Following these sales, the reporting person beneficially owns 3,023,982 shares, held directly.

Axon Enterprise (AXON) filed its Q3 2025 10‑Q, reporting net sales of $710,641,000, up from $544,274,000 a year ago. Services contributed $305,242,000, while Connected Devices delivered $405,399,000, led by TASER at $237,950,000. Gross margin was $427,348,000, but higher operating expenses resulted in an operating loss of $2,129,000. Interest expense increased to $28,912,000, and the quarter closed with a net loss of $2,186,000 (basic and diluted $(0.03) per share).

Axon strengthened liquidity, ending with cash and cash equivalents of $1,423,871,000 and short‑term investments of $952,786,000. Financing activity was significant: the company issued $1,750,000,000 in new notes, generated $362,241,000 of net proceeds from an equity offering, and repurchased a portion of its 2027 convertible notes, reducing that principal to $282,528,000. Deferred revenue totaled $1,003,606,000.

The backlog remains sizable, with approximately $8.1 billion in remaining performance obligations, of which the company expects to recognize about “20% - 25%” over the next 12 months. Shares outstanding were 78,910,466 as of October 31, 2025.